BioLamina is a Stockholm-based biotech scale-up specializing in matrix biology and cell culture. Founded in 2009, the company develops and manufactures high-quality, chemically defined, and animal-origin-free human recombinant laminin-based cell culture substrates. These substrates are designed to enable the reliable growth and differentiation of pluripotent stem cells and other primary cells, which are crucial for advancing cell therapies for serious chronic diseases and enhancing the precision of cell-based models in drug discovery and development. BioLamina's products, such as Biolaminin® substrates, are used in cell therapy development, including clinical trials.
